Phathom Pharmaceuticals, Inc. (PHAT) - Form 8-K Summary
Business Context and Reporting Period
Phathom Pharmaceuticals, Inc., a Delaware corporation, filed this Current Report on Form 8-K on February 26, 2026. The filing serves to announce the company's financial results for the quarter and full year ended December 31, 2025. The detailed results are contained in a press release attached as Exhibit 99.1.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being included in the attached press release (Exhibit 99.1) but are not present in the body of this 8-K document.
Material Changes
No specific material changes versus prior periods are detailed in this filing text. The document solely references the issuance of the press release containing the comparative financial data.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer under General Instruction B.2 of Form 8-K. It states that the information in this report, including the attached press release, is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section. Consequently, specific guidance, management commentary, risks, or contingencies are not detailed in this text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, net loss, and cash position figures for Q4 and FY 2025.
- Verify the company's cash runway and burn rate as disclosed in the full press release.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the attached exhibit.
- Confirm the status of any debt obligations or financing activities referenced in the full financial results.